Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder, characterized by a lack of dystrophin. To eliminate the need for immunosuppressive drugs, transplantation of genetically modified autologous myoblasts has been proposed as a possible therapy for this myopathy. An HSV-1 amplicon vector (HSVDGN), containing a 17.3-kb full-length MCK-driven mouse dystrophin cDNA, an eGFP gene, and a neomycin resistance gene driven by CMV or SV40 promoters, respectively, was constructed and used to transduce mdx primary myoblasts. The presence of the eGFP and neomycin resistance genes facilitated the evaluation of the initial transduction efficiency and the permanent transduction frequency. At low multiplicities of infection (MOI 1-5), the majority of myoblasts (60-90%) expressed GFP. The GFP-positive mdx myoblasts were sorted by FACS and selected with neomycin (300 µg/ml) for 2 weeks. Up to 2% of initially infected mdx myoblasts stably expressed the three transgenes without further selection at that time. These altered cells were grafted into the tibialis anterior muscles of 18 mdx mice. Some of the mice were immunosuppressed with FK506 due to the anticipation that eGFP and the product of neomycin resistance gene might be immunogenic. One month after transplantation, numerous muscle fibers expressing mouse dystrophin were detected by immunohistochemistry, in both immunosuppressed (10-50%) and nonimmunosuppressed (5-25%) mdx mice. Our results demonstrated the capability of permanently expressing a full-length dystrophin in dystrophic myoblasts with HSV-1 amplicon vector and raised the possibility of an eventual treatment of DMD based on the transplantation of genetically modified autologous myoblasts. 759 760 BUJOLD ET AL.
INTRODUCTION
skeletal muscle fibers due to a nonsense mutation in the dystrophin gene (5) .
Duchenne muscular dystrophy (DMD) occurs in about
Since the discovery of dystrophin deficiency as the 1 out of 3500 male births. This disease is due to a mutamolecular basis of DMD (20), many studies have been tion of the dystrophin gene and causes progressive skelundertaken in an attempt to restore the expression of etal and cardiac muscle degeneration (11). Dystrophin is dystrophin expression in dystrophic muscles. These ina subsarcolemmal protein associated with a large oligoclude direct delivery of a mini or full-length dystrophin meric complex of glycoproteins called dystrophin-assogene with a variety of vectors and transplantation of ciated proteins (DAPs). This complex provides a linkage myoblasts containing an intact dystrophin gene. Howbetween the subsarcolemmal cytoskeleton with the exever, to date only limited success has been achieved by tracellular matrix (30, 31, 40) . The linkage between the both approaches. The problems for the direct gene delivsubsarcolemmal cytoskeleton and the extracellular maery are that several vectors commonly used for gene trix is disrupted by the lack of dystrophin in dystrophic therapy are unable to efficiently transduce differentiated muscles. Although it does not exactly mimic the human muscle cells because of either low diffusion in muscles, phenotype, the mdx mouse is a good animal model to inadequate vector capacity for the full-length dystrophin study DMD because it lacks dystrophin and DAPs in its cDNA, or requirement for cell division for integration and expression by the vector or a combination thereof and a DNA cleavage/packaging signal (pac) in addition to the desired gene(s) and its plasmid backbone. The (1) (2) (3) 8, 12, 34) . Transplantation of allogeneic normal myoblasts into dystrophic muscles has been shown to re-amplicon vector is as easy to manipulate as any mammalian expression vector and the large DNA capacity of store dystrophin expression in a certain percentage of dystrophic myofibers in animal experiments (41) but has HSV-1 virion (152 kb) provides minimal limitation to the size of desired transgene (56) . In the presence of failed in all the clinic trials (18, (21) (22) (23) 29, 33, 51) . A vital problem of this therapeutic approach is the large im-HSV-1 genome in trans, amplicons can be efficiently packaged into HSV-1 virions (15, (48) (49) (50) . The HSV-1 mune response against the injected allogeneic myoblasts after transplantation, and this immune response was re-genome with its packaging signal (pac) deleted can be carried by either a BAC or a set of cosmids, and when sponsible in part for the failures. The specific immune response can be controlled with immunosuppressive the modified HSV-1 genome and amplicon are cotransfected into packaging cells only amplicon virions are treatments such as FK506 (24, 25, 47) and cyclosporine (32, 33) , but these immunosuppressive drugs produce se-made. Amplicons use the rolling circle mechanism of replication, producing serial head-to-tail concatamers vere adverse effects (6,52) and the patient becomes immunoincompetent. Therefore, it would be preferable not that are cleaved at pac signals into the ϳ152-kb unit length genome required to fill the virus capsid. Conse-to use immunosuppression.
Transplantation of genetically modified autologous quently, each amplicon vector particle delivers, depending on the size of the seed amplicon, a "pseudo genome" myoblasts has been proposed as a possible solution to avoid long-term use of immunosuppressive drugs. Meth-with multiple copies of the gene(s) of interest, and, depending on the design of the amplicon, this can be ex-ods used for direct gene therapy could be used to genetically modify the cells before such cells are reimplanted pressed using a tissue-specific or generic promoter. Because the modified HSV-1 genome lacks the packag-into the muscles. Both retrovirus and the adeno-associated virus (AAV) have the advantage as integrative vec-ing signal, it is not packaged into HSV-1 virions. Therefore, this protocol allows the production of amplicon-tors but have insufficient encapsidation capacity to insert the full-length dystrophin cDNA. A truncated version of derived virions that are infectious, replication deficient, and devoid of all viral genes, thereby eliminating most the dystrophin gene has been reported to be delivered into dystrophic myoblasts by retroviral vector in vitro viral toxicity. HSV-1 amplicon vectors packaged by this protocol have been demonstrated to be capable of trans-(9,10). However, the titer of this retrovirus is very low and these results have not been confirmed in our labora-ducing a broad range of cells (15, 56) , including muscle cells (59) , without interfering with their normal func-tory. Also, it is preferable to transduce a full-length dystrophin rather than a truncated one in which the gene tions. The present article describes an amplicon vector that transduces three transcriptional units including a product only partially restores the function of dystrophin protein. Adenovirus is a commonly used gene therapy full-length mouse dystrophin cDNA into mdx myoblasts. A small percentage of the transduced mdx myoblasts was vector and can accept the full-length dystrophin cDNA. However, the use of the adenovirus (Ad) to deliver able to stably express the transgenes when grafted into the tibialis anterior (TA) muscles of mdx mice. These genes in muscle fibers also has its limitations. First, the first-generation Ad vector induces an immune reaction myoblasts restored persistent dystrophin expression in significant fractions of myofibers in the grafted TA mus-(53), especially because high titers of the recombinant virus are required for successful myoblast transduction (1, cles even without immunosuppression. We demonstrate here for the first time that HSV-1 amplicon vectors are 2,7,44, 45, 55) . Moreover, one report showed that high multiplicity of infection (MOI) was toxic for cultured capable of stably transducing large genes such as dystrophin and the feasibility of autologous myoblast trans-myoblasts and inhibited differentiation (27) . Second, although mdx and DMD myoblasts have been genetically plantation. modified by transducing the dystrophin mini-gene or the MATERIALS AND METHODS full-length dystrophin gene with an Ad vector, expanded
Construction and Packaging of Vector in culture and grafted into mdx hosts (13, 35) , this viral vector did not integrate into the genome and the expres-pHSVGN (gift of Dr. Xandra O. Breakefield, Massachusetts General Hospital, Boston, MA) is an amplicon sion was rapidly lost.
HSV-1 amplicon vectors have been found capable of vector containing an eGFP gene driven by a human CMV promoter and an neomycin resistance gene driven infecting and expressing transgenes in muscle cells in vitro and in vivo (58, 59) . Ex vivo at a MOI of 5, an by a SV40 promoter (14). A 17.3-kb BssHII-flanked fragment from pCVAA (gift of Dr. Jeffrey S. Chamber-HSV-1 amplicon vector is able to transduce the majority of myoblasts and myotubes in the culture. This vector lain, University of Washington, Seattle, WA), encoding a full-length mouse dystrophin and an MCK promoter, contains only the HSV-1 origin of DNA replication (ori) was inserted into pHSVGN. The resulting amplicon, pH-Myoblast Transplantation and Tissue Processing SVDGN, was 26.3 kb in size and was packaged into Dystrophin and β-galactosidase were delivered to the HSV-1 virions with helper virus-free packaging system TA of mdx mouse using myoblast transplantation of ei- (15) and yielded a reasonable titer of 2 × 10 6 transducther genetically corrected mdx myoblasts with HSV-1 tion unit (t.u.)/ml in crude stock, which was slightly amplicon vector pHSVDGN or primary TnI LacZ mylower than the titer of the original amplicon, HSVGN oblasts. The myoblasts were detached from their growth (5 × 10 6 t.u./ml). flask with 0.1% trypsin followed by three suspensions in HBSS and centrifugation (3000 rpm, 5 min). The fi-Muscle Cell Culture, Gene Transduction, and Stable nal cell pellet was diluted in 1 ml of HBSS. Prior to Colony Generation transplantation the recipient mice were anesthetized with 80 mol of a solution containing 10 mg/ml of ketamine The mdx myoblasts were isolated from mdx mice (42) and 10 mg/ml xylazine. The skin was opened to expose and grown in Ham's F10 medium supplemented with the TA muscle. Genetically modified mdx myoblasts or 20% fetal calf serum (FCS) and 5 ng/ml basic fibroblast TnI LacZ myoblasts were suspended in 15 ml of notexin growth factor (bFGF, Promega, Medison, WI). To induce (5 mg/ml, Sigma) and injected with a glass micropipette differentiation, the growth medium was changed to in the right and left TA of mdx mice, respectively. Each DMEM supplemented with 2% heat-inactivated horse TA muscle of the mdx mice was injected at 25-30 sites serum (HIHS). The mdx myoblasts were infected with with a total of about 3 × 10 6 myoblasts. The skin was amplicon vector HSVDGN at MOI of 1 and 5, respecthen closed with fine sutures. One month after myoblast tively. The GFP-positive myoblasts were sorted by transplantation, mice were killed by intracardiac perfu-FACS 24 h after infection. The sorted cells were grown sion with 0.9% NaCl solution with heparin (1.4 ng/ml, in growth medium and selected with 300 µg/ml G418 Sigma) under deep anesthesia of 10 mg/ml ketamine and for 2 weeks. The surviving colonies were also GFP posi-10 mg/ml xylazine. The specimens were embedded in tive. The stable transduction efficiency was calculated OCT (Shandon) and frozen in liquid nitrogen. Serial by dividing the number of surviving colonies with the cryostat cross-sections of the muscles (12 µm thick) number of cells plated and normalized by the efficiency were thawed on gelatin-coated slides. Dystrophin was of colony formation of the primary mdx myoblasts. Six detected on adjacent cryostat sections of the muscles of colonies were picked up and grown without further sethe mdx mice with a monoclonal antibody against dyslection for 2 months before the termination of the cultrophin (NCL-Dys-2, Novocastra inc., Newcastle, UK) ture.
followed by a secondary biotinylated antibody against mouse IgM (Dako). This secondary antibody was de-Immunocytochemistry and Western Blot to Detect tected with streptavidine-Cy3 (Sigma). A M.O.M. Kit Dystrophin Expression (Vector Laboratories, Inc.) was used with the antibody Some of the myoblasts were induced to differentiate, to remove the background binding of the anti-mouse anand immunocytochemistry to detect the expression of tibody. The TA muscles grafted with TnI LacZ cells dystrophin with polyclonal antibody 6-10 (26) was per-(left leg) were fixed in 0.25% glutaraldehyde and stained formed as described previously (38) . The expression of in 0.4 mmol/L X-Gal in an incubator overnight at 37°C dystrophin was also evaluated by Western blot analysis to detect the β-galactosidase activity. using standard methods as described previously (59) .
RESULTS Briefly, an equal amount of total proteins from wildtype myotubes, and mdx myotubes and genetic modified
In a previous study, we have shown that HSV-1 amplicon vector is able to transduce full-length mouse mdx myotubes was loaded onto polyacrylamide-SDS gel (6% resolving) (28) . Electrophoresis was carried out at dystrophin into dystrophic myotubes (59) . In this study, we further examined the capability of this vector system 85 mA for 4 h and then the gel was transferred to PVDF membrane (Millipore). The membrane was first treated to stably transduce primary mdx myoblasts ex vivo with a full-length mouse dystrophin cDNA and grafted them with 5% nonfat milk and then incubated with polyclonal antibody 6-10 (20) at a 1:5000 dilution for 2 h at room in mdx mice. We successfully constructed an amplicon vector containing the full-length dystrophin cDNA driven temperature (RT). After being washed thoroughly, the membrane was incubated with HRP-conjugated anti-by a muscle-specific MCK promoter and enhancer, as well as an eGFP and a neomycin resistance cassette rabbit IgG secondary antibody (Amersham Life Science) at 1:5000 dilution for 1 h at RT. The membrane was driven by viral promoters (CMV and SV40), for a total size of 26.3 kb (Fig. 1) . The vector was packaged and incubated with SuperSignal ultra chemiluminescent substrate (Pierce) for 5 min and then exposed to a BioMax resulted in a reasonable titer (2 × 10 6 t.u./ml in unconcentrated stock and 10 8 t.u./ml after concentration). The film (Kodak). virions were used to infect mdx myoblasts at MOIs of 1 and 5, resulting in 60-90% of infected myoblasts expressing eGFP 24 h after infection. The GFP-positive myoblasts infected at MOI 1 were sorted by FACS and plated at clonal density with 300 µg/ml G418, selecting for 2 weeks. After 2 weeks of selection all the remaining cell clones expressed GFP and the stable transduction efficiency was 0.4-2%. Six clones of eGFP-positive mdx myoblasts were isolated and cultured without further selection. The cells continued to express eGFP in the absence of G418 until the culture was terminated 2 months later (Fig. 2, Ia) . These myoblasts were differentiated into contracting myotubes that were GFP positive (Fig. 2, Ib) . Immunocytochemistry proved that these myotubes also expressed mouse dystrophin (Fig. 2, Ic,  d) . Western blot analysis further proved that the dystrophin protein expressed from the transgene was of the correct size and the level of expression from those genetically modified mdx myotubes was the same as wildtype myotubes (Fig. 2, II) .
The mdx dystrophin-positive clones were further expanded 3 weeks to obtain 55 × 10 6 mdx dystrophin-positive myoblasts. Two weeks before transplantation, the left and right hind legs of the recipient mice were irradiated (20 Gy) to avoid host myoblast proliferation (36, 37, 61) . Eighteen male mdx mice, approximately 1 month old, were used for this experiment. To monitor the success of transplantation, primary murine myoblasts, which expressed β-galactosidase, were isolated from neonatal TnI LacZ mice and transplanted as positive graft controls into the TA muscle of the opposite limb. Both genetically modified mdx myoblasts and TnI LacZ myoblasts were suspended in 15 mml of notexin (5 mg/ml) and injected with a glass micropipette in the right and left TA of mdx mice, respectively. Notexin has been product of the neomycin resistance gene, and β-galacto-sidase, as all of these proteins are potentially immuno-many as 2% of transduced mouse primary myoblasts, the vector DNA persisted in the nuclei and was dupli-genic. FK506 was administered intramuscularly, beginning on the day of the myoblast transplantation and cated during cell divisions. Although there were some technical difficulties in providing direct evidence of the maintained until animals were sacrificed (1 month). Seven grafted mdx mice were not immunosuppressed. This genomic integration of the vector DNA due to the unusual size of this vector (26.3 kb), we have observed work was authorized by the Laval University Animal Care Committee and was conducted according to the that the cancatemer of HSV-1 amplicon vectors integrated into the cellular genome as a whole piece in guidelines set by the Canadian Council of Animal Care.
One month after myoblast transplantation, the mice a similar experiment (57) . The other group has also obtained the same result using Pulse Field Gel Electro-were sacrificed. TA muscles were removed and then processed for β-galactosidase and dystrophin analysis. phoresis technique followed by Southern blot analysis (Dr. Bakowska, personal communication). In the present The success of myoblast transplantation in the mdx mice was initially determined in the muscle transplanted with study, the myoblasts studied divided more than 50 divisions in the absence of selection before being grafted. TnI LacZ control. Abundant β-galactosidase-positive (90%) (Fig. 3a, b ) and dystrophin-positive fibers (50%) Therefore, this observation sustains the hypothesis that the vector DNA has been integrated into the cellular ge- (Fig. 3c, d, e ) were observed in the muscles of the immunosuppressed mice, proving that the graft protocol nome.
In the present vector, the eGFP expressed by the vec-and the immunosuppression were successful. Ten to 50% of the fibers in the TA muscles that received genet-tor facilitated the evaluation of the initial and stable transduction efficiencies and the neomycin resistance ically engineered mdx myoblasts and treated with FK506 were dystrophin positive (Fig. 3d, e ). The newly formed enabled us to discover the stable transduction capability of amplicon vectors, which has not been described be-fibers were correctly oriented and distributed throughout the muscle. A slightly lower percentage of dystrophin-fore. However, in the future vector design, expressing both genes permanently should be avoided because their positive fibers (5-25%) was observed in the TA muscles of mdx mice transplanted with genetically engineered protein products might be immunogenic to the hosts. In fact, some immune cell infiltration in the TA muscles mdx myoblasts but not immunosuppressed with FK506 (Fig. 3g, h) .
receiving grafts was observed in this study. We feel that this was most likely induced by eGFP and/or neomycin A mild infiltration by T lymphocytes (0-100 T lymphocytes per section) was observed in the muscles in-resistance proteins rather than by dystrophin, because our previous study showed that dystrophin itself did not jected with genetically modified myoblasts, indicating an immune rejection. A little stronger infiltration (100-cause T-lymphocyte infiltration, although 50% of the mdx mice did developed antibodies against dystrophin 300 T lymphocytes per section) was observed in the nonimmunosuppressed mice ( Fig. 3i ) than in the immu- (54) . However, because the vector only stably transduces a small fraction of infected myoblasts, a selection nosuppressed group (Fig. 3f ). This result can be explained by the fact that eGFP and neomycin resistance is necessary. In future vector designs, we will solve this by expressing the selection gene temporarily through gene are immunogenic for the mouse and caused this increased reaction. No β-galactosidase-positive fibers transcriptional regulation by using a promoter of either a muscle differentiation factor, such as MyoD or Myo-were observed in the muscles grafted with TnI LacZ myoblasts in the nonimmunosuppressed group. However, genin ( (16, 17, 46) , or Pax 7 (42), which allows the expression of the selection gene in myoblasts but will turn despite the lymphocyte infiltration in the contralateral muscles in the nonimmunosuppressed mice transplanted it off after the grafted myoblasts fuse into myofibers. Thus, a temporary use of immunosuppressing drug will with genetically engineered mdx myoblasts, dystrophinpositive fibers were observed in the mice 1 month after be sufficient to control the potential immunoreaction triggered by the protein products of the selection gene(s). transplantation. Some infiltration was also observed in the immunosuppressed mice, demonstrating that FK506
Another alternative might be to use human origin select genes such as human dihydrofolate reductase (DHFR) is not 100% effective in controlling the immune reaction.
gene, which has been shown to be able to eliminate the immunorejection to the selecting gene (43).
DISCUSSION
More interestingly, in the present study, we demonstrated that the HSV-1 amplicon vector was able to HSV DNA has been believed to exist in an unstable nonepisomal and nonintegrated state in the nuclei of in-transduce not only the full-length dystrophin gene but also at least two other genes from the same vector. This fected cells. Such DNA would be diluted out during cell divisions and would preclude long-term expression in will allow us to transduce the myoblasts with other genes that could improve the efficiency of transplanta-dividing cells. However, our results showed that in as tion. For example, if we transduce a telomerase gene vide a powerful tool to genetically manipulate dystrophic myoblasts ex vivo and potentially to overcome the together with the dystrophin gene, the transduced myoblasts will also have the ability to proliferate better previously demonstrated obstacles in myoblast transplantation. after transplantation and compete with exhausted native dystrophic myoblasts. As another example, if we were Whether the dystrophin itself is immunogenic to the dystrophic individual has been a controversial topic. We to transduce an insulin-like growth factor I (IGF-I) gene, which has been shown to enhance muscle regeneration previously reported successful transplantation of wildtype syngeneic myoblasts in mdx mice without immuno-and synthetic pathway (4), and alternatively, an additional nitric oxide synthase (NOS) gene, which has been suppression (54) . Another group has reported evidence of a cellular immune reaction in a similar experiment shown to have anti-inflammatory and cytoprotective function (60), the transduced myoblasts will not only (39). Because all previous autologous myoblast transplantations with myoblasts expressing dystrophin from proliferate and fuse to form myofibers better but also produce NO to protect the area that received the grafts an adenoviral vector failed to express dystrophin for a sustained period (13,35), it could not be determined and the newly formed myofibers from inflammatory injury. Thus, the unusual ability to transduce both large whether this was due to an immune response or loss of vector DNA or transgene expression. Although the and multiple genes of HSV-1 amplicon vectors will pro- 
